You are here:

Voriconazole 50mg and 200mg tablets, 40mg/ml oral suspension, and 200mg vials (Vfend®) for infusion

Advice

Following a full submission.

Voriconazole (Vfend®) is accepted for restricted use within NHS Scotland for the treatment of candidaemia in non-neutropenic patients.

Voriconazole provides an additional agent for the treatment of candidaemia in non-neutropenic patients.Its use is restricted to patients with fluconazole-resistant Candida infection who do not respond to, or cannot tolerate amphotericin B therapy or who are at an increased risk of serious side-effects with amphotericin.

Drug Details

Drug Name: Voriconazole 50mg and 200mg tablets, 40mg/ml oral suspension, and 200mg vials (Vfend®) for infusion
SMC Drug ID: 194/05
Manufacturer: Pfizer Ltd
Indication: Candidaemia in non-neutropenic patients
BNF Category:
Sub Category: 5.2 Antifungal Drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 8 August 2005

Back